Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera

Blood

Volumn 128, Issue 18, 2016, Pages 2266-2270

  Lanikova, Lucie ^a,b,c   Babosova, Olga ^c   Swierczek, Sabina ^a,b   Wang, Linghua ^d   Wheeler, David A ^d   Divoky, Vladimir ^e,f   Korinek, Vladimir ^c   Prchal, Josef T ^a,b,g  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e PALACKÝ UNIVERSITY   (Czech Republic)

^f MASARYK UNIVERSITY   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GANDOTINIB; HYDROXYUREA; JANUS KINASE 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; JAK2 PROTEIN, HUMAN; PHENYLALANINE; VALINE;

BLAST TRANSFORMATION; BURST FORMING UNIT E; CLINICAL ARTICLE; DNA SEQUENCE; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GERMLINE MUTATION; GRANULOCYTE; HETEROZYGOTE; HUMAN; LETTER; LEUKOCYTOSIS; MALE; PANCYTOPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SANGER SEQUENCING; TREATMENT REFUSAL; AMINO ACID SUBSTITUTION; CELL CULTURE; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; GENETICS; MISSENSE MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; CELLS, CULTURED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; GERM-LINE MUTATION; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; PHENYLALANINE; POLYCYTHEMIA VERA; POLYMORPHISM, SINGLE NUCLEOTIDE; VALINE;

EID: 85015164274     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-04-711283     Document Type: Letter

References (25)

1. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97-105.
2. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
3. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
4. Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia. 2014;28(4):935-938.
5. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601-612.
6. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32.e1-32.e9.
7. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380.
8. Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. Leukemia. 2014;28(4): 938-941.
9. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7): 1073-1081.
10. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006;43(4):295-305.
11. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30(17):3894-3900.
12. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361-362.
13. Wallweber HJ, Tam C, Franke Y, Starovasnik MA, Lupardus PJ. Structural basis of recognition of interferon-a receptor by tyrosine kinase 2. Nat Struct Mol Biol. 2014;21(5):443-448.
14. Ma L, Clayton JR, Walgren RA, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013;3:e109.
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
16. Etheridge SL, Cosgrove ME, Sangkhae V, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood. 2014;123(7):1059-1068.
17. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372-1383.
18. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967-969.
19. Kapralova K, Horvathova M, Pecquet C, et al. Cooperation of germline JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood. 2016;128(10):1418-1423.
20. Zhao L, Ma Y, Seemann J, Huang LJ. A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochem J. 2010;426(1):91-98.
21. Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol. 2008;28(5):1792-1801.
22. Witzig TE, Price-Troska TL, Stenson MJ, Gupta M. Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained. Leuk Lymphoma. 2013;54(2):397-399.
23. Hudson AM, Yates T, Li Y, et al. Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Res. 2014;74(22): 6390-6396.
24. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
25. Pearse RN, Feinman R, Ravetch JV. Characterization of the promoter of the human gene encoding the high-affinity IgG receptor: transcriptional induction by gamma-interferon is mediated through common DNA response elements. Proc Natl Acad Sci USA. 1991;88(24):11305-11309.